Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study.
about
Role of aflibercept for macular edema following branch retinal vein occlusion: comparison of clinical trialsClinical Trials in Branch Retinal Vein OcclusionIndividualized Treatment of Neovascular Age-Related Macular Degeneration: What are Patients Gaining? Or Losing?Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conberceptStrategies for Improving Patient Comfort During Intravitreal Injections: Results from a Survey-Based Study.EFFICACY AND SAFETY OF INTRAVITREAL CONBERCEPT INJECTIONS IN MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION.Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials.VEGF: From Discovery to Therapy: The Champalimaud Award Lecture.Comparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: a network meta-analysis.[Retinal vein occlusion: Therapy of retinal vein occlusion].Intravitreal steroid and anti-vascular endothelial growth agents for the management of retinal vein occlusion: evidence from randomized trials.Retina specialists treating cystoid macular oedema secondary to retinal vein occlusion recommend different treatments for patients than they would choose for themselves.Effect of leaking capillaries and microaneurysms in the perifoveal capillary network on resolution of macular edema by anti-vascular endothelial growth factor treatment.Functional-morphological parameters, aqueous flare and cytokines in macular oedema with branch retinal vein occlusion after ranibizumab.Metamorphopsia Associated with Branch Retinal Vein OcclusionGrid laser with modified pro re nata injection of bevacizumab and ranibizumab in macular edema due to branch retinal vein occlusion: MARVEL report no 2.Estimation of the need for bilateral intravitreal anti-VEGF injections in clinical practice.Sterile Inflammation after Intravitreal Injection of Aflibercept in a Korean Population.Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases.Five-year outcomes of pars plana vitrectomy for macular edema associated with branch retinal vein occlusionAflibercept: A Review in Macular Oedema Secondary to Branch Retinal Vein Occlusion.Aflibercept Traps Galectin-1, an Angiogenic Factor Associated with Diabetic RetinopathyComparison between anti-VEGF therapy and corticosteroid or laser therapy for macular oedema secondary to retinal vein occlusion: A meta-analysis.Cost-Effectiveness of Ranibizumab Versus Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: A UK Healthcare PerspectiveComparison of the Efficacy of Intravitreal Aflibercept and Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion.Association between retinal hemorrhagic pattern and macular perfusion status in eyes with acute branch retinal vein occlusion.Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion.The Royal College of Ophthalmologists Guidelines on retinal vein occlusions: executive summary.Long-term results of combination therapy using anti-VEGF agents and dexamethasone intravitreal implant for retinal vein occlusion: an investigational case series.Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion.Anti-angiogenic Therapy for Retinal Disease.Switch of Intravitreal Therapy for Macular Edema Secondary to Retinal Vein Occlusion from Anti-VEGF to Dexamethasone Implant and Vice Versa.Short-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab.SCORE2 Report 5: Vision-Related Function in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion.Outcome of "treat and monitor" regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion.Bevacizumab versus Dexamethasone Implant Followed by Bevacizumab for the Treatment of Macula Edema Associated with Branch Retinal Vein Occlusion.Blood coagulation parameters after intravitreal injection of aflibercept in patients with neovascular age-related macular degeneration.Macular cystic changes as predictive factor for the recurrence of macular oedema in branch retinal vein occlusion.A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion.Aflibercept in branch retinal vein occlusion as second line therapy: clinical outcome 12 months after changing treatment from bevacizumab/ranibizumab-a pilot study.
P2860
Q26750459-919406F0-7881-45CB-A7F5-5C1C2CFCA3E9Q26767092-0C118F32-DC25-4178-9380-D3C934AEE47BQ26799492-D0ECB206-B4AE-4854-9396-B8E17C2929C2Q28075557-91155D50-4578-4F81-BC14-1613490EC5AFQ30391349-7075CDF2-9D1C-4EAC-A0C4-335EE9DD9A4AQ30490419-80CD876C-06BD-40F4-8007-DB83C0113E3EQ31155420-CF9D07D5-4754-4536-B5F6-E5B0C8F4E55DQ34518374-82C29A32-4B5D-49A8-9295-921395991FE5Q35655005-038EF4BB-F2F5-4949-BB59-3D8EAF9350A3Q35737854-299D0D04-6711-4DDE-AD50-534A19E04129Q35769968-225E2865-D102-40B8-BC9E-E3EA15A6216DQ35882307-76F300D4-6C27-4724-A93F-88C81DC118C5Q35902075-6AE5592E-EFB2-4735-9A1E-2E8800AB32DBQ35988002-E054BB4C-D70C-450F-8DE9-1A74CF1BC95DQ36001663-24B8C0D0-C175-4F92-AE09-23B2D0B169B0Q36058492-A2985188-A8F2-4ED6-B923-0DEBC60B34D1Q36099741-46DF482D-DC22-42FE-9E82-BAFC55A3222FQ36127283-FDB56452-19EB-4D58-8279-B4CA97717F18Q36200924-2D5BA548-AA0D-4E4D-8641-2A7620B7FCDCQ36296091-DD92D768-3D92-4390-9239-D565C2D9BF9CQ36331045-C9A7D6DC-2439-44E2-BDCD-7CC5A0AAF3D8Q36357723-99E6FC84-1DA3-4CE2-99AA-6FFDEEEC7EDAQ36412013-FDED45FE-40E4-47E4-9CD3-136830A3CC46Q36526922-C54A6DCE-3906-425D-960D-DB0E66C2457AQ36835209-F0A81C4A-DA00-4ABC-B134-D296A4D71EE6Q37030777-0D327120-7D56-4025-9B1B-EBF88E934C9DQ37288622-E3365F26-C192-4411-8259-462751E5F8FDQ37457117-46EF2BAC-5036-4F35-B73D-B9B0FDD41286Q37530866-8E000F52-808E-461C-90D1-79D02BDAB2AFQ37669520-8FFB0812-729E-4D27-9D3E-987DBB65871FQ38805247-917C0FD1-6E86-4F99-88D0-7D49826C908DQ41371210-EDEE3D22-83DE-4387-A6D5-DFD7893E1467Q41767272-1BE4A891-04C5-42F4-BA98-C5AB78232442Q46777540-3291246D-299E-41EF-9FFC-D3445E814997Q48352897-D1782293-D6FD-4EE2-BE35-3F7C40DB6D78Q49619345-7C2B741D-F987-472A-A213-503B7F1D219EQ50062366-08B9B05F-8586-40EE-9526-C89C5B634DDDQ50859000-72E52258-EEED-4303-9A33-10EE717733B3Q53199049-16383A38-31D4-4521-9969-8A25D8BC63F0Q55073223-DE64C225-9A81-4BFE-A18C-94D8DD3ADDCA
P2860
Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Intravitreal aflibercept for m ...... results of the VIBRANT study.
@ast
Intravitreal aflibercept for m ...... results of the VIBRANT study.
@en
type
label
Intravitreal aflibercept for m ...... results of the VIBRANT study.
@ast
Intravitreal aflibercept for m ...... results of the VIBRANT study.
@en
prefLabel
Intravitreal aflibercept for m ...... results of the VIBRANT study.
@ast
Intravitreal aflibercept for m ...... results of the VIBRANT study.
@en
P2093
P1433
P1476
Intravitreal aflibercept for m ...... results of the VIBRANT study.
@en
P2093
Alyson J Berliner
David M Brown
David S Boyer
Husain Kazmi
Jeffrey S Heier
Julia A Haller
Karen W Chu
Kristine Erickson
Peter A Campochiaro
Robert Vitti
P304
P356
10.1016/J.OPHTHA.2014.08.031
P577
2014-10-12T00:00:00Z